Spero Therapeutics, Inc. (NASDAQ:SPRO) Director Sells $53,990.82 in Stock

Spero Therapeutics, Inc. (NASDAQ:SPRO) Director Ankit Mahadevia sold 69,219 shares of Spero Therapeutics stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $0.78, for a total value of $53,990.82. Following the transaction, the director now directly owns 689,866 shares in the company, valued at approximately $538,095.48. The trade was a 9.12 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Spero Therapeutics Price Performance

NASDAQ SPRO opened at $0.82 on Friday. The business’s fifty day moving average is $0.99 and its 200-day moving average is $1.19. The stock has a market capitalization of $44.62 million, a price-to-earnings ratio of 11.69 and a beta of 0.61. Spero Therapeutics, Inc. has a one year low of $0.74 and a one year high of $1.89.

Analyst Ratings Changes

A number of equities analysts have issued reports on SPRO shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Spero Therapeutics in a report on Friday, November 15th. TD Cowen reissued a “hold” rating on shares of Spero Therapeutics in a research report on Monday, November 18th. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Spero Therapeutics in a research report on Thursday, January 30th. Finally, Evercore ISI cut shares of Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 target price on the stock. in a research report on Friday, December 20th.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.